ScreenerHero

INM InMed Pharmaceuticals Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · inmedpharma.com
1.330USD0.00%Mkt Cap: 7.31M $P/E: —

InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States. The company researches and develops cannabinoid-based pharmaceuticals products. Its product candidates include INM-90…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$66.23BUSDP/E 25.7
TAK
Takeda Pharmaceutical Company Limited
$58.68BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.70BUSDP/E 65.3
GALD
Galderma Group AG
$43.27BUSDP/E 56.1
HLN
Haleon plc
$39.67BUSDP/E 18.4
SDZ
Sandoz Group AG
$34.93BUSDP/E 60.5
HLN
Haleon plc
$32.73BUSDP/E 19.0
ZOE
Zoetis Inc.
$28.56BUSDP/E 12.2
ZTS
Zoetis Inc.
$29.57BUSDP/E 11.8
UTHR
United Therapeutics Corporation
$23.38BUSDP/E 19.5
VTRS
Viatris Inc.
$20.09BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.43BUSDP/E 112.9
NBIX
Neurocrine Biosciences, Inc.
$14.58BUSDP/E 21.0
IPN
Ipsen S.A.
$12.99BUSDP/E 23.5
ELAN
Elanco Animal Health Incorporated
$11.17BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.22BUSDP/E 27.9
KRK
Krka, d. d.
$8.66BUSDP/E 19.3
ALKS
Alkermes plc
$6.95BUSDP/E 109.1
HIMS
Hims & Hers Health, Inc.
$6.89BUSD
AMRX
Amneal Pharmaceuticals, Inc.
$6.84BUSDP/E 40.1

Key Statistics

Company
Market Cap7.31M USD
Enterprise Value5.07M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-12.56M USD
Revenue/Share—
Last Price1.330 USD
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees6
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.21
PEG—
EV/EBITDA-0.52
EV/Revenue—
P/S—
P/B6.62
EPS (TTM)-2.84
EPS (Forward)-6.25
52W Range
0.575039% of range2.500
52W High2.500 USD
52W Low0.5750 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-1168.44%
ROA-414.54%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-8.64M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-43.62%
Net Debt-2.23M USD
Net Debt/EBITDA0.23
Balance Sheet
Debt/Equity0.00
Current Ratio1.37
Quick Ratio1.14
Book Value/Sh0.20 USD
Cash/Share0.41 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJul 6, 2020
Splits
Last Split1:20
Split DateNov 14, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.5.49M
Float3.13M
Insiders0.06%
Institutions51.38%
Short Interest
Short Ratio0.2d
Short % Float0.29%
Short % Out.0.29%
Shares Short15.88K
Short (prev mo.)72.43K
Technical
SMA 501.413 (-5.9%)
SMA 2001.181 (+12.6%)
Beta0.93
S&P 52W Chg16.45%
Avg Vol (30d)53.95K
Avg Vol (10d)52.37K
Technical Indicators
RSI (14)42.8
MACD-0.0215
MACD Signal-0.0235
MACD Hist.+0.0020
BB Upper1.414 USD
BB Middle1.344 USD
BB Lower1.274 USD
BB Width10.39%
ATR (14)0.0667 USD
Vol Ratio (20d)0.20x